Your shopping cart is currently empty

Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $205 | In Stock | In Stock | |
| 5 mg | $497 | In Stock | In Stock | |
| 10 mg | $690 | In Stock | In Stock | |
| 25 mg | $1,000 | In Stock | In Stock |
| Description | Lefradafiban(BIBU-104) is an oral platelet glycoprotein IIb/IIIa receptor antagonist for the study of angina pectoris and acute coronary syndromes. |
| In vivo | Lefradafiban (30, 45, and 60 mg; oral; three times daily for 48 hours; patients with stable angina undergoing angioplasty) is an effective oral glycoprotein IIb/IIIa receptor blocker.[1] |
| Synonyms | BIBU-104, BIBU104, BIBU 104 |
| Molecular Weight | 439.46 |
| Formula | C23H25N3O6 |
| Cas No. | 149503-79-7 |
| Smiles | C(NC(OC)=O)(=N)C1=CC=C(C=C1)C2=CC=C(OC[C@@H]3C[C@@H](CC(OC)=O)C(=O)N3)C=C2 |
| Relative Density. | 1.32g/cm3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 45 mg/mL (102.4 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.